Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
96 Leser
Artikel bewerten:
(0)

USALCO Announces Executive Transition With Hassan Mela Appointed as CFO

Finanznachrichten News

USALCO, LLC, a leading provider of water treatment solutions, has appointed Hassan Mela as its new Chief Financial Officer, replacing John Sobchak, who will retire later in 2025. Mela brings extensive experience in finance and leadership roles from his previous positions at Nouryon, Honeywell, and Deloitte. He holds a B.A. in Accounting and an M.S. in Information Systems from Michigan State University, and he is also a CPA and Six Sigma Certified Green Belt.

BALTIMORE, MARYLAND / ACCESS Newswire / January 22, 2025 / USALCO, LLC ("USALCO" or the "Company"), a leading provider of water treatment solutions for municipal and commercial customers, announced today the appointment of Hassan Mela as Chief Financial Officer, replacing John Sobchak who had earlier announced his intent to retire.

Ken Gayer, USALCO CEO, said, "Hassan is an experienced leader with a long track record of partnering with teams and driving financial and operational results in chemical and industrial companies." Mr. Mela added, "I am delighted to join the strong team at USALCO and excited about working with management and the board to execute the next stage of growth."

Previously, Mr. Mela served as Vice President-Finance and Chief Accounting Officer, and Interim Group CFO at Nouryon, a global specialty chemicals company, where he played an important role in supporting enterprise-wide transformation. Prior to Nouryon, Hassan spent eight years in senior finance positions at Honeywell, including Vice President, Global Controller, and Chief Financial Officer of the Performance Materials and Technologies (PMT) Division. Mr. Mela began his career at Deloitte, last serving as a senior manager within the Industrials' practice. He received his B.A. in Accounting and M.S. with specialization in Information Systems from the Broad College of Business at Michigan State University. Hassan is a Certified Public Accountant (CPA) and a Six Sigma Certified Green Belt.

John Sobchak joined USALCO as CFO in early 2021. Mr. Sobchak built a world-class Finance Team at USALCO and was key to the Company's transformation from a strong mid-Atlantic aluminum chemicals company into the leading supplier of coagulants to the U.S. water treatment industry. It has been a true pleasure and privilege to work with John," said Mr. Gayer. "John has had a long and accomplished career, serving in the CFO role at various public and private companies over the last 25 years, including several very successful private equity exits." Mr. Sobchak will continue with USALCO in a transitional role and assist with specific projects in the company's pipeline before retiring later in 2025.

About USALCO

USALCO is a leading provider of water treatment solutions for municipal and commercial customers in the United States, offering bespoke formulated chemistries and leading product efficacy to address a diverse range of water treatment requirements. Headquartered in Baltimore, MD, USALCO operates 33 manufacturing and distribution facilities throughout the United States. Visit https://www.usalco.com/ for more information.

Contact Information

Trevor Hildebrandt
Vice President Marketing
thildebrandt@usalco.com

.

SOURCE: USALCO



View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.